Clinical trials: Withdrawal
High Frequency Episodic Migraine and Chronic Migraine
TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine
This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
- Trial name
- NCT01839149
- Testing
- TI-001
- Where
- 6 sites in Australia, Chile and 1 more
- Volunteers
- 240 people
- Sponsor
- Trigemina, Inc
Psoriasis
BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
This was a multinational, multicenter, randomized, double-blind, placebo controlled study with randomized withdrawal and retreatment, evaluating the safety and efficacy of risankizumab 150 mg subcutaneous (SC) in participants…
- Trial name
- NCT02672852
- Testing
- Risankizumab
- Volunteers
- 507 people
- Sponsor
- AbbVie
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
- Trial name
- DAPPER (NCT01511978)
- Testing
- Continuous 3,4-DAP
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jacobus Pharmaceutical
Colorectal Neoplasms
Gluteal Squeeze for Left Colon Distension
Good distension of the colon during colonoscopy is essential to detect polyps. Gas sometimes escapes the colon through the anus resulting in compromised distension.
- Trial name
- NCT04827485
- Testing
- Gluteal squeeze, No squeeze
- Where
- 2 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Obesity / Overweight
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
This is an observational cohort study. The primary objective is to analyze the dynamic changes in gut microbiota and metabolic profiles in obese patients treated with Tirzepatide.
- Trial name
- NCT07847515
- Testing
- Tirzepatide
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Cannabis Use, Depression
Cannabis, Linked Emotions, and Adolescent Risk Study
The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of…
- Conditions
- Cannabis Use, Depression, Suicidal Ideation, Adolescent Behavior
- Trial name
- CLEAR (NCT06576076)
- Testing
- Contingency management for cannabis abstinence
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
Secondary Amenorrhea
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
- Trial name
- NCT00160199
- Testing
- PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Solvay Pharmaceuticals
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Cannabis Withdrawal
Effect of PP-01 on Cannabis Withdrawal Syndrome
This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to…
- Trial name
- NCT05494437
- Testing
- PP-01 High Dose, PP-01 Low Dose, Nabilone
- Where
- 18 sites in United States
- Volunteers
- 234 people
- Sponsor
- PleoPharma, Inc.
Cystic Fibrosis
Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study
Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be…
- Trial name
- SIMPLIFY-DN (NCT06350474)
- Testing
- Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
- Where
- 81 sites in United States
- Volunteers
- 477 people
- Sponsor
- Nicole Hamblett
Heart Transplantation
Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation
The purpose of this study is first to improve or save renal function and second to decrease cardiac risk factors by optimising the immunosuppressive regimen by withdrawing steroids and reducing the Cyclosporine A dose.
- Trial name
- NCT00359658
- Testing
- prednisolon, Mycophenolatmofetile, Cyclosporin A
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke
Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI
The goal is to pilot test a highly accessible, web-based, pragmatic, scalable intervention to overcome ongoing problems with high stakes decision-making by surrogate decision-makers of patients in ICUs with severe acute brain…
- Conditions
- Hemorrhagic Stroke, Intracerebral, Acute Ischemic Stroke, Traumatic Brain Injury
- Trial name
- NCT05671874
- Testing
- Web/mobile/tablet-based digital decision aid + communication (DA+C) tool
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Neonatal Opioid Withdrawal Syndrome
CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome
A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome
- Trial name
- NOWSHINE (NCT04104646)
- Testing
- CHF6563, Morphine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Rheumatoid Arthritis
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience
Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require…
- Trial name
- NCT03109470
- Sponsor
- Pope Research Corporation
Alcohol Use Disorder
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
In alcohol use disorder (AUD) and matched healthy control (HC) men and women, the proposed research examines the effects of MIFE, with demonstrated preclinical effects on drinking-related behaviors, compared with placebo on a…
- Trial name
- NCT02989662
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Neurostimulation to Improve NOWS Outcomes
The objective of this study is to determine if tAN therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.
- Trial name
- SPROUT (NCT05129020)
- Testing
- Sparrow Fledging Therapy System
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Spark Biomedical, Inc.
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo…
- Trial name
- NCT03420781
- Testing
- Relamorelin
- Where
- 337 sites in United States, Argentina and 24 more
- Volunteers
- 467 people
- Sponsor
- Allergan
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06108544
- Testing
- TAK-279, Apremilast
- Where
- 217 sites in United States, Argentina and 14 more
- Volunteers
- 1,108 people
- Sponsor
- Takeda
Colon Polyp, Colorectal Adenoma
9 Minutes for Tandem Colonoscopy Withdrawal
A mean withdrawal time of at least 6 minutes has been considered to be one of the critical quality criterions of colonoscopy. Recently, our group completed a multicenter randomized controlled trial, which proved that prolonging…
- Trial name
- NCT04797065
- Testing
- 6-minute then 9-minute withdrawal, 9-minute then 6-minute withdrawal
- Where
- China
- Volunteers
- 733 people
- Sponsor
- Changhai Hospital
Living Donor Liver Transplantation
DCreg in Living Donor Liver Transplantation
Phase I/II, single center, prospective, open-label, non-controlled, non-randomized, interventional, cohort study in which low risk living donor liver transplant (LDLT) recipients will receive a single infusion of donor-derived…
- Trial name
- NCT03164265
- Testing
- Regulatory Donor-Derived Dendritic Cell infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Angus W. Thomson PhD DSc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.